Kwon Y W, Franckowiak G, Langs D A, Hawthorn M, Joslyn A, Triggle D J
Department of Biochemical Pharmacology, School of Pharmacy, State University of New York, Buffalo 14260.
Naunyn Schmiedebergs Arch Pharmacol. 1989 Jan-Feb;339(1-2):19-30. doi: 10.1007/BF00165121.
The structure-activity relationships of a series of 1,4-dihydropyridine Ca2+ channel activators, including Bay K 8644, have been determined by pharmacologic and radioligand binding techniques. Pharmacologic techniques included tension responses and the measurement of pA2 values for nifedipine antagonism of Bay K 8644 responses in guinea pig ileal, rat femoral and rat atrial and papillary muscle preparations. Radioligand binding experiments employed competition against [3H]nitrendipine binding in ileal smooth muscle and rat ventricular membranes and rat brain synaptosomal preparations. The series of compounds was employed as the racemates. Binding affinities were not significantly different between smooth muscle, cardiac muscle and brain preparations and the same rank order of pharmacologic activities is observed in smooth and cardiac muscle, where the effects of the 4-phenyl substituents, o greater than or equal to m greater than p, parallel those observed for 1,4-dihydropyridine antagonists. In the ileal and femoral artery smooth muscle preparations a 1:1 correlation is observed between pharmacologic and radioligand binding affinities. However, in the cardiac muscle preparations, left atrium and papillary muscle, there is an approximately 10-fold difference between the binding affinities and the lower pharmacologic affinities. A similar difference between smooth and cardiac muscle is observed with the pA2 values of 6.97 and 7.06 in atrial and papillary muscle respectively, which are significantly lower than the values of 8.54 and 8.72 measured in ileal and femoral artery respectively. The structure-activity expressions measured for this small series of 1,4-dihydropyridine activators parallel those observed in the larger series of 1,4-dihydropyridine antagonists. This is consistent with proposals that activators and antagonists interact at common binding sites that are components of a voltage-dependent Ca2+ channel.
包括Bay K 8644在内的一系列1,4 - 二氢吡啶类钙离子通道激活剂的构效关系已通过药理学和放射性配体结合技术确定。药理学技术包括张力反应以及在豚鼠回肠、大鼠股动脉、大鼠心房和乳头肌制备物中硝苯地平对Bay K 8644反应拮抗作用的pA2值测量。放射性配体结合实验采用在回肠平滑肌、大鼠心室膜和大鼠脑突触体制备物中与[3H]尼群地平结合竞争的方法。该系列化合物以消旋体形式使用。平滑肌、心肌和脑制备物之间的结合亲和力无显著差异,并且在平滑肌和心肌中观察到相同的药理活性排序,其中4 - 苯基取代基的效应(邻位≥间位>对位)与1,4 - 二氢吡啶拮抗剂所观察到的平行。在回肠和股动脉平滑肌制备物中,观察到药理学亲和力与放射性配体结合亲和力之间呈1:1相关性。然而,在心肌制备物(左心房和乳头肌)中,结合亲和力与较低的药理学亲和力之间存在约10倍的差异。在心房和乳头肌中分别测得的pA2值为6.97和7.06,与在回肠和股动脉中分别测得的8.54和8.72相比显著更低,在平滑肌和心肌之间也观察到类似差异。这一小系列1,4 - 二氢吡啶激活剂测得的构效关系表达式与在较大系列1,4 - 二氢吡啶拮抗剂中观察到的平行。这与激活剂和拮抗剂在作为电压依赖性钙离子通道组成部分的共同结合位点相互作用的提议一致。